2024-01-30 15:00:23 ET
Pfizer Inc. (PFE)
Q4 2023 Results Conference Call
January 30, 2024 10:00 AM ET
Company Participants
Francesca DeMartino - Chief Investor Relations Officer
Albert Bourla - Chairman and Chief Executive Officer
David Denton - Chief Financial Officer
Aamir Malik - Executive VP & Chief U.S. Commercial Officer
Alexandre de Germay - Executive VP & Chief International Commercial Officer
Mikael Dolsten - Chief Scientific Officer and President of Research & Development
Chris Boshoff - Executive VP & Chief Oncology Officer
Conference Call Participants
Robyn Karnauskas - Truist Securities
Carter Gould - Barclays
Louise Chen - Cantor Fitzgerald
Trung Huynh - UBS
Terence Flynn - Morgan Stanley
Umer Raffat - Evercore ISI
Tim Anderson - Wolfe Research
Andrew Baum - Citigroup
Geoff Meacham - Bank of America
Mohit Bansal - Wells Fargo
Steve Scala - TD Cowen
David Risinger - Leerink Partners
Chris Schott - JPMorgan
Rajesh Kumar - HSBC
Kerry Holford - Berenberg
Chris Shibutani - Goldman Sachs
Akash Tewari - Jefferies
Evan Seigerman - BMO Capital Markets
Presentation
Operator
Good day, everyone, and welcome to Pfizer's Fourth Quarter 2023 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.
Francesca DeMartino
Good morning. And welcome to Pfizer's earnings call. I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our results for the fourth quarter and full-year 2023 via press release that is available on our website at pfizer.com.
I'm joined today by Dr. Albert Bourla, our Chairman and CEO; and Dave Denton, our CFO. Albert and Dave have some prepared remarks and we will then open the call for questions. Joining for the Q&A session, we will also have Dr. Chris Boshoff, EVP and Chief Oncology Officer; Alexandre de Germay, EVP and Chief International Commercial Officer; Dr. Mikael Dolsten, Chief Scientific Officer and President of R&D; Doug Lankler, EVP and General Counsel; and Aamir Malik, EVP and Chief U.S. Commercial Officer.
Before we get started, I wanted to remind you that we will be making forward-looking statements and discussing certain non-GAAP financial measures. I encourage you to read the disclaimers in our slide presentation, the press release we issued this morning and the disclosures in our SEC filings which are all available on the IR website on pfizer.com.
Forward-looking statements on the call are subject to substantial risks and uncertainties speak only as of the call's original date and we undertake no obligations to update or revise any of these statements.
With that, I will turn the call over to Albert.
Albert Bourla
Thank you, Francesca. Good morning, everyone and thank you for joining us. I'm pleased to discuss some of the highlights from the fourth quarter and full-year 2023, and of course, a compelling year we have ahead. I’d like to begin with a few reflections on 2023.
As you know, we missed our initial internal projections and Street expectations predominantly related to our COVID products, which affected our stock price performance. Despite however this challenging year, there were a few great things that happened in 2023 that may have gotten lost amidst the mixed expectations....
Read the full article on Seeking Alpha
For further details see:
Pfizer Inc. (PFE) Q4 2023 Earnings Call Transcript